通行寶(301339.SZ):正在開發“蘇超”IP系列產品
格隆匯7月7日丨通行寶(301339.SZ)在投資者互動平臺表示,公司持續關注江蘇省城市足球聯賽及相關熱點,正在開發“蘇超”IP系列產品,包括手辦款ETC、城市吉祥物等周邊產品,將ETC功能創新與城市文化符號、球迷情感需求深度融合,兼具收藏價值與實用價值。目前相關產品已完成設計開發,進入生產階段,預計於7月正式推出,並同步開展線上線下多場景的立體式營銷。公司未來將以城市文化爲靈魂、科技創新爲載體、賽事場景爲引擎,將ETC從功能工具升級爲情感聯結介質,努力構建“城市IP-出行經濟-交通生態”的商業閉環。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.